Skip to main content
Equibles
AUPH logo

AUPH · Aurinia Pharmaceuticals Inc.

Track AUPH — free

Use AUPH with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$16.08 -0.04 (-0.25%) At close · Sep 4
Russell 2000 member Rebalance outlook locked
Market Cap
$2.14B
Shares
133.05M

AUPH metrics

73 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$16.08
Market cap
$2.14B

Price action

19 metrics
Price change (1W)
-1.3%
Price change (30D)
+4.1%
Price change (3M)
+1.5%
Price change (6M)
+12.3%
Price change (YTD)
+0.8%
Price change (1Y)
+28.3%
Trailing year
Price change (5Y)
-8.3%
52-week high
$18.62
52-week low
$11.05
Change from 52-week high
-13.6%
Change from 52-week low
+45.5%
Annualized volatility
41.3%
Beta
0.7
RSI (14D)
50.9
Price vs SMA 50
+1.5%
Price vs SMA 200
+3.8%
Avg volume (3M)
1.38M
Relative volume
0.4
Average dollar volume
$22.42M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
133.05M

Valuation

12 metrics
P / E (TTM)
7.0
Trailing earnings · reciprocal yield 14.2%
PEG ratio
0.1
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
6.9×
reciprocal yield 14.6%
P / book
3.5
reciprocal yield 28.7%
FCF yield
—
TTM · current market cap
Buyback yield
3.9%
P / FCF
—
P / operating cash flow
12.2
reciprocal yield 8.2%
Earnings yield
14.7%

Historical valuation

8 metrics
P / E historical average (3Y)
35.4×
reciprocal yield 2.8%
P / E historical average (5Y)
35.4×
reciprocal yield 2.8%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
3.9%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-02-26

Profitability

9 metrics
Gross margin
90.4%
Operating margin
48.4%
Trailing 12 months
Net margin
100.8%
Gross profit (TTM)
—
Operating profit (TTM)
$150.75M
Net income (TTM)
$314.11M
Trailing 12 months
Diluted EPS (TTM)
$2.29
FCF margin
—
Effective tax rate
-95.9%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.67

Growth

11 metrics
Revenue growth YoY
+18.9%
Year over year
Net income growth YoY
+73.9%
Revenue (TTM)
$311.51M
Trailing 12 months
EPS growth YoY
+75.0%
Shares change YoY
-2.9%
Year over year · fewer shares
Revenue CAGR (3Y)
+28.3%
Revenue CAGR (5Y)
+41.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
51.1%
Return on assets
39.6%
Debt / equity
—
Current ratio
5.4
EBITDA (TTM)
$170.13M
Free cash flow (TTM)
—
Quick ratio
5.0
Interest coverage
36.7
Net debt / EBITDA
-1.1
Return on invested capital
—
Trailing 12 months
Net cash
$179.73M
Latest balance sheet
Cash & equivalents
$179.73M
Total assets
$792.26M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$175.24M
Capital expenditures (TTM)
—
R&D (TTM)
$39.85M
SG&A (TTM)
—
Stock compensation (TTM)
$14.62M
R&D / revenue
12.8%
Stock compensation / revenue
4.7%

Ownership (13F)

3 metrics
13F filers
283
13F filer change QoQ
+21
Institutional ownership
60.6%

Short interest

3 metrics
Short interest
7.2%
Latest settlement · 8.0 days to cover
Days to cover
8.0d
Short-squeeze score
73 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$355,946
Insider-sentiment score
44 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1600620 CUSIP 05156V102 13F (30d) 175 filings 174 filers Visit website Investor relations